APA (7th ed.) Citation

MS, K., M, Z., MO, N., AM, G., E, A., LK, A., . . . S, L. (2022). Systemic high-dose dexamethasone treatment may modulate the efficacy of intratumoral viral oncolytic immunotherapy in glioblastoma models. Journal for immunotherapy of cancer, 10(1), . https://doi.org/10.1136/jitc-2021-003368

Chicago Style (17th ed.) Citation

MS, Koch, et al. "Systemic High-dose Dexamethasone Treatment May Modulate the Efficacy of Intratumoral Viral Oncolytic Immunotherapy in Glioblastoma Models." Journal for Immunotherapy of Cancer 10, no. 1 (2022). https://doi.org/10.1136/jitc-2021-003368.

MLA (9th ed.) Citation

MS, Koch, et al. "Systemic High-dose Dexamethasone Treatment May Modulate the Efficacy of Intratumoral Viral Oncolytic Immunotherapy in Glioblastoma Models." Journal for Immunotherapy of Cancer, vol. 10, no. 1, 2022, https://doi.org/10.1136/jitc-2021-003368.